Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
Philippines evacuates 100,000 people as super typhoon declared
Major US air traffic staffing shortages cancels thousands of flights
Afghanistan-Pakistan peace talks collapse, ceasefire continues, Taliban says
UPS, FedEx ground MD-11 fleets after deadly Louisville crash
US warns it could force 20% flight cuts if shutdown continues
